EKF Diagnostics Holdings plc (AIM:EKF)

Market Cap	103.62M -6.6%
Revenue (ttm)	51.35M +2.3%
Net Income	2.50M -59.2%
EPS	0.01 -57.9%
Shares Out	428.24M
PE Ratio	42.51
Forward PE	14.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,614
Open	24.20
Previous Close	24.40
Day's Range	24.20 - 24.20
52-Week Range	21.80 - 29.00
Beta	0.50
Analysts	Strong Buy
Price Target	34.67 (+43.29%)
Est. Earnings	Dec 16, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 308
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.

Analyst Summary

According to 3 analysts, the average rating for EKF stock is "Strong Buy." The 12-month stock price target is 35p, which is an increase of 43.29% from the latest price.

Price Target

35p

(43.29% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error